{
    "symbol": "AMRX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-05 15:46:10",
    "content": " It is worth noting that the second quarter of 2021 was our highest generics revenue quarter last year, benefiting from timing of numerous large new product launches such as  From a sequential perspective, Q2 generics net revenue of $365 million increased by $47 million or 15%, reflecting growth, like before of injectables and Adrenaclick, as our global supply and commercial teams ensured solid, growing and consistent supply of this highly complex and high medical need products."
}